Versifel FeLV
Active substance
ATC code
Species
Cats.
Indications
For active immunization of susceptible cats from 9 weeks of age to reduce the number of cats infected with FeLV and presenting clinical signs of the related disease.
No data are available in the studies to demonstrate protection against related clinical disease but prevention of infection is associated with protection against related clinical disease.
Onset of immunity occurs within four weeks of the completion of the primary vaccination course.
The duration of immunity is at least one year after the primary course and three years after the booster.
Dose to be administered and administration route
Subcutaneous use.
Shake the vial well immediately before use.
Primary vaccination:
Two doses of 1 mL should be administered subcutaneously to cats from nine weeks of age, with an interval of 3-4 weeks between doses.
Re-vaccination:
A single booster dose should be administered 1 year after the completion of the primary vaccination course. Thereafter a single booster dose should be administered to cats once every 3 years.
For concurrent vaccination with Zoetis’ Versifel CVR, a single dose of Versifel FeLV should be administered as described above. A single dose of Zoetis’ Versifel CVR should then be administered at a separate site via the subcutaneous route.
For simultaneous vaccination with Zoetis’ Versifel CVR, the contents of a single vial of Zoetis’Versifel CVR should be reconstituted with the contents of a single vial of Versifel FeLV in place of the diluent. Once mixed, the contents of the vial should appear as a slightly coloured (pink/orange) opaque suspension; the mixed vaccines should be injected immediately via the subcutaneous route.
Adverse reactions
Commonly, small subcutaneous swellings have occurred at the injection site, (diameter usually smaller than 10 mm, maximal diameter 20 mm) and very rarely may be associated with a brief period of discomfort and/or pain. The majority of these swellings resolve within a short period (2 weeks). A small proportion may remain detectable for 1 to 2 months however, by this time they are very small.
Commonly, following the first subcutaneous administration in the target species, transient increases in temperature could occur (up to 40.5°C after administration of an overdose); such temperature rises are however expected to be of short duration (resolving within 48 hours). Frequency and duration of any temperature rise is usually lower following subsequent administrations.
When administered concurrently or simultaneously with Zoetis’ Versifel CVR transient increases in temperature (up to 40.5 °C) are common following first vaccination lasting up to 5 days.
Following the second dose administration, on rare occasions transient enlargements of the pre-scapular lymph nodes have been observed; such enlargements are small in size (0.5 cm diameter) and only detected upon palpation of the area following injection.
Very rarely, a brief period of general malaise or mild or moderate depression is observed immediately post vaccination but normally resolves within 24 hours; health of animals is not adversely affected.
Very rarely, digestive tract disorders such as: vomiting, diarrhoea or anorexia has been observed.
In very rare cases allergic reactions have been observed. In case of anaphylactic shock appropriate treatment should be administered.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment).
- common (more than 1 but less than 10 animals in 100 animals).
- uncommon (more than 1 but less than 10 animals in 1,000 animals).
- rare (more than 1 but less than 10 animals in 10,000 animals).
- very rare (less than 1 animal in 10,000 animals, including isolated reports).
